NASH (non-alcoholic steatohepatitis)

NaTiV-3

EU CT Number: 2020-004986-38 

Recruitment currently closed

A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis

Objective

Histological decrease in fibrosis (NAS score -2 points) / healing of inflammation

We are looking for patients with:

  • Metabolic Syndrome (Diabetis type 2, hypertension, hypercholesterolemia)
  • liver steatosis (Fibroscan >6kPa)
  • no liverdiesea (e.a. Hep B /C)
  • no liver cirrhosis

If you are interested in the study, please speak to your GP or specialist doctor. You can also contact us directly by email or via the contact form for more information.

Contact

Akero

EU CT Number: 2023-505141-48-00

Recruitment is open

Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-3-Studie zur Bewertung der Sicherheit und Wirksamkeit von Efruxifermin bei Patienten mit nicht-zirrhotischer nicht-alkoholischer Steatohepatitis (NASH)/metabolischer Dysfunktion-assoziierter Steatohepatitis (MASH) und Fibrose.

Objective

Histological decrease in fibrosis (NAS score -2 points) / healing of inflammation

We are looking for patients with:

  • Metabolic Syndrome (Diabetis type 2, hypertension, hypercholesterolemia)
  • liver steatosis (Fibroscan >6kPa)
  • no liverdiesea (e.a. Hep B /C)
  • no liver cirrhosis

If you are interested in the study, please speak to your GP or specialist doctor. You can also contact us directly by email or via the contact form for more information.

Contact